Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EvolvE: Barzolvolimab in Eosinophilic Esophagitis
NCT05774184Phase 2Completed
- Sponsor
- Celldex Therapeutics
- Start
- Jun 2023
- Primary completion
- Jun 2025
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial in eosinophilic esophagitis (EoE) comparing Barzolvolimab (CDX-0159) with Placebo then barzolvolimab (CDX-0159) 300mg (2 arms). Primary endpoint: Peak intraepithelial mast cell count at 12 weeks. Started Jun 2023; status: completed.
02
Drugs
barzolvolimab
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NCT05774184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05774184.